Marijuana safe to treat epilepsy in kids: Study

Image
IANS
Last Updated : Aug 13 2018 | 1:25 PM IST

Consuming a marijuana-based drug may be safe in treating children with severe epilepsy, results of a clinical trial has showed.

Following treatment with cannabidiol -- a non-psychoactive compound found in marijuana -- about one in five children were described as much or very much improved from their baseline, while around half reported none, or a very slight improvement, Xinhua news agency reported.

While the trial was conducted on a small group of children with severe epilepsy, it showed that the drug had a manageable side effect profile, but only showed extensive symptom relief for a brief number of patients.

The trial "involved the sickest children with epilepsy -- children who are having seizures many times per day, who have been recently hospitalized for their epilepsy, and have failed on average about nine anti-epilepsy drugs before," said lead author John Lawson, paediatric neurologist at Sydney's Children's Hospital.

"The main aim of the study was about safety. We found that there were a few safety concerns but overall those safety issues were very manageable and the drug overall was very safe for the majority," he added.

The study was published in the Medical Journal of Australia.

Although legally cannabis must be prescribed by a doctor, recent reports of cannabis derivatives being successful in treating children with epilepsy have led to a number of parents of sick children sourcing their own medical marijuana.

While the study's authors said the results were significant, they stressed that the purpose of this study was about safety not efficacy.

The US Food and Drug Administration had recently approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy -- Lennox-Gastaut syndrome and Dravet syndrome -- in patients two years of age and older.

--IANS

asj/rt/mag/sed

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 13 2018 | 1:22 PM IST

Next Story